Lygina Elena, Morgacheva Daria, Khadela Avinash, Postwala Humzah, Shah Yesha, Dinikina Yulia
Department of Chemotherapy for Hematologic Diseases and Bone Marrow Transplantation for Children, Almazov National Medical Research Centre, St. Petersburg 197341, Russia.
Department of Pharmacology, L.M. College of Pharmacy, Navrangpura, Ahmedabad, Gujarat 380009, India.
Oncol Lett. 2023 Mar 30;25(5):194. doi: 10.3892/ol.2023.13780. eCollection 2023 May.
Medulloblastoma (MB) is one of the most common pediatric malignant tumors arising from the central nervous system with an unknown etiology and variable prognosis. Relapsed or refractory MB in pediatric patients after intensive anticancer therapy (chemo-, radiotherapy) is associated with treatment resistance and poor survival prognosis. Metronomic chemotherapy in combination with mTOR inhibitors may have advantages due to an alternate mechanism of cytotoxicity and a favourable adverse effects profile. Furthermore, it is considered to be a prospective anticancer regimen regardless of the presence/absence of molecular targets. The present study reported a successful result of this treatment option with optimal tolerability in relapsed MB in a pediatric male patient and highlighted the advantages for a selected group of patients.
髓母细胞瘤（MB）是最常见的起源于中枢神经系统的儿童恶性肿瘤之一，其病因不明，预后各异。儿童患者在接受强化抗癌治疗（化疗、放疗）后出现复发或难治性MB与治疗耐药及不良生存预后相关。节拍化疗联合mTOR抑制剂可能具有优势，因为其细胞毒性作用机制不同，且不良反应较轻。此外，无论是否存在分子靶点，它都被认为是一种有前景的抗癌方案。本研究报告了一名男性儿童复发性MB患者采用这种治疗方案取得了成功，耐受性良好，并强调了该方案对特定患者群体的优势。
